Gallbladder Cancer (MSK, Cancer 2018)

Summary

Gallbladder Cancer (MSK, Cancer 2018) is a study catalogued by cBioPortal DataHub under the cancer-type code gbc. EvidenceHelix groups it with liver, bile duct and gallbladder studies.

Study description

Targeted Sequencing of 103 samples with matched normals from 101 Gallbladder cancer patients.

Text as published in the source's study metadata.

Citation & PubMed

Raja et al, Cancer 2018

Linked PubMed records: PMID 30427539

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

gbc_msk_2018

Short name

GBC (MSK CANCER 2018)

Source cancer-type code

gbc

Reference genome

not given

Source access groups

PUBLIC

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Raja et al, Cancer 2018

• PubMed record 30427539 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Gallbladder Cancer (MSK, 2022)

  Targeted sequencing of 244 Gallbladder cases via MSK-IMPACT where investigators calculated the Overall survival time for 100 metastatic gallbladder patients.

  Liver, bile duct and gallbladderMSK studiesSource code gbcPubMed 1

• Gallbladder Carcinoma (Shanghai, Nat Genet 2014)

  Whole exome sequencing of 32 gallbladder carcinoma tumor/normal pairs.

  Liver, bile duct and gallbladderOther published and consortium studiesSource code gbcPubMed 1

• Cholangiocarcinoma (MSK, Clin Cancer Res 2018)

  Targeted sequencing (MSK-IMPACT) of 195 tumor samples (194 with matched normals) from 192 cholangiocarcinoma patients.

  Liver, bile duct and gallbladderMSK studiesSource code cholPubMed 1

• Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)

  MSK-IMPACT sequencing of 127 Hepatocellular Carcinoma tumor samples with matched normals.

  Liver, bile duct and gallbladderMSK studiesSource code hccPubMed 1

• Hepatocellular Carcinoma (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 1,370 hepatobiliary cancer samples (with 1366 matched normals) via MSK-IMPACT. This data is available under the Creative Commons BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-…

  Liver, bile duct and gallbladderMSK studiesSource code hccPubMed 1

• Hepatocellular Carcinoma (MSK, JCO Precis Oncol 2023)

  Targeted sequencing of 51 hepatocellular carcinoma patients and their matched normal samples via MSK-IMPACT.

  Liver, bile duct and gallbladderMSK studiesSource code hccPubMed 1

• Intrahepatic Cholangiocarcinoma (MSK, Clin Cancer Res 2021)

  Targeted sequencing of IMPACT and CMO samples

  Liver, bile duct and gallbladderMSK studiesSource code ihchPubMed 1

• Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)

  Targeted sequencing of 412 intrahepatic cholangiocarcinoma tumor/normal sample pairs.

  Liver, bile duct and gallbladderMSK studiesSource code ihchPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.